Discovery and characterization of actionable tumor antigens

Genome Medicine

Claude Perreault¹  Grégory Ehx¹ 

[1]0000 0001 2292 3357, grid.14848.31, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, H3T 1J4, Montreal, Quebec, Canada

[2]0000 0001 2292 3357, grid.14848.31, Department of Medicine, Université de Montréal, H3T 1J4, Montreal, Quebec, Canada

DOI  :  10.1186/s13073-019-0642-x

来源: publisher

【 摘 要 】

l summaryThe nature of the tumor antigens that are detectable by T cells remains unclear. In melanoma, T cells were shown to react against major histocompatibility complex (MHC)-associated peptides (MAPs) that are derived from exonic mutations. A recent multi-omic study of hepatocellular carcinomas suggests, however, that mutated exonic MAPs were exceedingly rare, bringing the accuracy of the current methods for antigen identification into question and demonstrating the importance of broadening tumor-antigen discovery efforts.

【 授权许可】

CC BY